Treatment With AMD3100 (Plerixafor) in MM Patients to Mobilize PBCs For Collection and for Transplantation
Status:
Terminated
Trial end date:
2007-05-01
Target enrollment:
Participant gender:
Summary
This study will examine whether 240 µg/kg plerixafor given alone for up to 4 days is safe and
well tolerated in multiple myeloma (MM) patients. In addition, this study determines if
plerixafor alone can be used to mobilize peripheral blood progenitor cells (PBPCs) for
transplantation in MM patients. The minimum number of CD34+ cells to collect is 2*10^6 CD34+
cells/kg and the target is ≧4*10^6 CD34+ cells/kg. Success of transplant engraftment will be
measured by the number of days to polymorphonuclear leukocytes (PMN) and platelet (PLT)
engraftment. Durability of transplant will be assessed for a minimum of one year.